Syquant Capital’s AbCellera Biologics ABCL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
– Sell
-70,000
Closed -$1.54M – 43
2021
Q2
$1.54M Buy
+70,000
New +$1.93M 1.85% 15

Other funds holding ABCL

Syquant Capital's ABCL Position: Q3 2021 in Review

Syquant Capital sold out of AbCellera Biologics (ABCL) in Q3 2021, closing a stake of 70,000 shares — an estimated $1.54M sold.

Syquant Capital first reported a position in ABCL in Q2 2021 and held it in 1 quarter. The position peaked at $1.54M in Q2 2021. 116 funds tracked by Wall St. Rank hold ABCL as of Q3 2021.

  • Syquant Capital reported no remaining AbCellera Biologics position as of Q3 2021 after selling out during the quarter.
  • Syquant Capital sold 70,000 AbCellera Biologics shares in Q3 2021, an estimated $1.54M.
  • Syquant Capital first reported a position in AbCellera Biologics in Q2 2021 and held it in 1 quarter.
  • Syquant Capital's AbCellera Biologics position peaked at $1.54M in Q2 2021.
  • 116 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2021.

Based on Syquant Capital's 13F filing for Q3 2021, filed 14 Oct 2021.